CKD-703 vs Vebreltinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
CKD-703
Developed by Chong Kun Dang Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2029 · NCT07439094 (registry estimate)
No aligned efficacy figure on record for this race.
Vebreltinib
Marketed by Avistone Biotechnology under a licence from Apollomics Inc.
NCT04258033 · Phase 2 · completed
This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly.
Next expected readout: December 2026 · NCT06343064 (registry estimate)
Reported efficacy
Objective response rate (2 years): Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee (met)
Result source: NCT04258033
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | CKD-703 | Vebreltinib |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06970782 |
| OS, median | —Not reported | —Trial running · NCT06970782 |
| ORR | —Not reported | —Trial running · NCT06970782 |
| Duration of response, median | —Not reported | —Trial running · NCT06970782 |
PFS, median
- CKD-703
- —Not reported
- Vebreltinib
- —Trial running · NCT06970782
OS, median
- CKD-703
- —Not reported
- Vebreltinib
- —Trial running · NCT06970782
ORR
- CKD-703
- —Not reported
- Vebreltinib
- —Trial running · NCT06970782
Duration of response, median
- CKD-703
- —Not reported
- Vebreltinib
- —Trial running · NCT06970782
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CKD-703: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-703's landscape · Vebreltinib's landscape